The monopoly that Myriad Genetics now enjoys (at least in USA) due to these patents reduces consumer choice and removes the competitive incentives regarding price, quality assurance, or improvement of the tests (just remember the case with large scale deletions which previous Myriad tests just missed before 2002). In my opinion human gene patents are intrinsically flawed – you can patent a technology and tools (e.g. test) but not a (natural) sequence.
In Europe there was (and still is) strong opposition against Myriad monopoly (alas this year they infringed patents for commercial use in largest European countries).
For those overseas – there are more cheaper testing options available via dedicated networks, like Gendia or Diagnogene.